There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lipocine (NASDAQ: LPCN), Viking Therapeutics (NASDAQ: VKTX) and Proteon (NASDAQ: PRTO) with bullish sentiments.
Lipocine (NASDAQ: LPCN)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Lipocine (NASDAQ: LPCN) today and set a price target of $3. The company’s shares closed yesterday at $1.14, close to its 52-week low of $1.03.
According to TipRanks.com, Livnat ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.0% and a 25.9% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Viking Therapeutics (NASDAQ: VKTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (NASDAQ: VKTX) today and set a price target of $11. The company’s shares closed yesterday at $4.24.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.0% and a 34.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Viking Therapeutics is Strong Buy and the average price target is $8.83, representing a 108.3% upside.
In a report issued on April 30, William Blair also initiated coverage with a Buy rating on the stock.
Proteon (NASDAQ: PRTO)
H.C. Wainwright analyst Swayampakula Ramakanth upgraded Proteon (NASDAQ: PRTO) to Buy today and set a price target of $3. The company’s shares closed yesterday at $2.10.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.2% and a 37.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Eleven Biotherapeutics, and IntelGenx Technologies.
Proteon has an analyst consensus of Moderate Buy, with a price target consensus of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
